Berberine for IBS with diarrhoea: a symptom study
What a berberine study found for diarrhoea frequency, abdominal pain and quality of life in adults with IBS.
Key points
- In adults with irritable bowel syndrome with diarrhoea, the mean diarrhoea-frequency measure fell by about 70% with berberine and 15% in the control group over eight weeks. Four weeks after stopping, no statistically significant difference between groups was detected. [1] See the evidence 1
- In the same group, abdominal-pain frequency decreased by about 65% with berberine and 29% in the control group, and the quality-of-life score increased more. These are changes in measures from the start of the study, not the proportion of people helped. [1] See the evidence 1 2
- Confidence in these results is very low; they concern adults with IBS and diarrhoea. When choosing a supplement, consider possible gastrointestinal reactions and medicines. [1] [2] [3] [4] [5] [6] See the evidence 1 2 3 4
Practical guide
Check the conclusions and whether they apply to your situation.
A study of adults with IBS and diarrhoea assessed symptom frequency and quality of life. These results apply to the specified group and regimen.
Key points
Why these conclusions
Diarrhoea, pain and quality of life in IBS
Adults with IBS with diarrhoea were given 200 mg berberine hydrochloride twice daily for eight weeks. The control group received matching-looking vitamin C tablets at 200 mg twice daily; the article called this a placebo. [1]
The diarrhoea-frequency measure from diaries fell by about 70% with berberine and 15% in the control group relative to baseline in each group. The difference was significant at week eight, but four weeks after stopping, no difference was detected. [1]
Abdominal-pain frequency fell from baseline by 64.6% with berberine and 29.4% in the control group. The IBS quality-of-life score rose by a mean of 36.27 and 4.94 points respectively; these three results came from one trial. [1]
Confidence in all three outcomes is very low, 1 out of 4: there was one study, some participants dropped out, and symptoms were recorded by participants themselves. The results concern adults with IBS with diarrhoea. [1]
Over eight weeks, the mean diary-based diarrhoea-frequency measure fell by about 70% with berberine and 15% in the control group. These are relative within-group changes calculated from the article’s table; berberine’s advantage at week eight was statistically significant. Four weeks after stopping, no statistically significant differences between groups were detected.
| Parameter | Data |
|---|---|
| Result | Over eight weeks, the mean diary-based diarrhoea-frequency measure fell by about 70% with berberine and 15% in the control group. These are relative within-group changes calculated from the article’s table; berberine’s advantage at week eight was statistically significant. Four weeks after stopping, no statistically significant differences between groups were detected. |
| Participants | Adults with irritable bowel syndrome with diarrhoea. 164 people were allocated, 82 per group; eight weeks were completed by 70 taking berberine and 62 in the control group. |
| Form | Berberine hydrochloride, tablets |
| Dose | 200 mg twice daily; 400 mg/day in total |
| Dose basis | 200 mg twice daily; 400 mg/day in total |
| Comparator | Matching-looking vitamin C tablets: 200 mg twice daily, 400 mg/day in total; the article called this control a placebo |
| Duration | Eight weeks of use, then four weeks of follow-up |
| Confidence | 1/4: Very low confidence: one small trial; 32 of 164 participants were not included in the final results. Participants recorded symptom frequency themselves, and complete results for those who dropped out are unavailable. |
| Evidence base | randomised trial |
| Sources | [1] |
Over eight weeks, diary-based abdominal-pain frequency decreased by 64.6% with berberine and 29.4% in the control group. This is the reduction from baseline within each group, not the percentage of people helped. The between-group difference at week eight was statistically significant.
| Parameter | Data |
|---|---|
| Result | Over eight weeks, diary-based abdominal-pain frequency decreased by 64.6% with berberine and 29.4% in the control group. This is the reduction from baseline within each group, not the percentage of people helped. The between-group difference at week eight was statistically significant. |
| Participants | Adults with irritable bowel syndrome with diarrhoea. 164 people were allocated, 82 per group; eight weeks were completed by 70 taking berberine and 62 in the control group. |
| Form | Berberine hydrochloride, tablets |
| Dose | 200 mg twice daily; 400 mg/day in total |
| Dose basis | 200 mg twice daily; 400 mg/day in total |
| Comparator | Matching-looking vitamin C tablets: 200 mg twice daily, 400 mg/day in total; the article called this control a placebo |
| Duration | Eight weeks of use |
| Confidence | 1/4: Very low confidence: results of one trial with substantial participant dropout. Several symptoms were assessed repeatedly; the result concerns pain frequency in IBS with diarrhoea. |
| Evidence base | randomised trial |
| Sources | [1] |
Over eight weeks, the score on an IBS-specific quality-of-life questionnaire rose on average from 122.20 to 158.47 with berberine and from 126.63 to 131.57 in the control group; higher scores mean better quality of life. Changes were +36.27 and +4.94 points respectively. The final between-group difference was statistically significant.
| Parameter | Data |
|---|---|
| Result | Over eight weeks, the score on an IBS-specific quality-of-life questionnaire rose on average from 122.20 to 158.47 with berberine and from 126.63 to 131.57 in the control group; higher scores mean better quality of life. Changes were +36.27 and +4.94 points respectively. The final between-group difference was statistically significant. |
| Participants | Adults with irritable bowel syndrome with diarrhoea. 164 people were allocated, 82 per group; eight weeks were completed by 70 taking berberine and 62 in the control group. |
| Form | Berberine hydrochloride, tablets |
| Dose | 200 mg twice daily; 400 mg/day in total |
| Dose basis | 200 mg twice daily; 400 mg/day in total |
| Comparator | Matching-looking vitamin C tablets: 200 mg twice daily, 400 mg/day in total; the article called this control a placebo |
| Duration | Eight weeks of use |
| Confidence | 1/4: Very low confidence: this is an additional questionnaire in one trial with participant dropout. Its results describe life with IBS and do not assess mood in healthy people. |
| Evidence base | randomised trial |
| Sources | [1] |
Information from the source
Berberine may cause abdominal pain or discomfort, nausea, vomiting, constipation and diarrhoea. Berberine should be avoided during pregnancy and breastfeeding; it is not given to infants. It may contribute to dangerous bilirubin accumulation in an infant, with brain damage. The French agency ANSES also recommends that children and adolescents and people with diabetes, liver disease or heart disease avoid berberine supplements. Severe heart-rhythm disturbances with QT interval prolongation on an ECG have been reported after berberine use. In one case, large doses of cannabinoid oil were taken at the same time; in another, arrhythmia occurred in an older man taking 500 mg berberine daily. Case reports do not show how often this happens, but fainting or pronounced palpitations require urgent medical assessment. In the six-month BRAVO trial, serious adverse events were recorded in 6 of 169 participants with berberine and 2 of 168 with placebo; the difference was not statistically significant. These events are not equivalent to proven adverse effects of berberine. Before the main part of the study, people who could not tolerate the run-in were excluded. [2] [3] [4] [5] [6]
Sources
- A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. https://pubmed.ncbi.nlm.nih.gov/26400188/
- In the News: Berberine. https://www.nccih.nih.gov/health/in-the-news-berberine
- ANSES Opinion on the safety of use of berberine-containing plants in the composition of food supplements — Request 2018-SA-0095. https://www.anses.fr/system/files/NUT2018SA0095EN.pdf
- Harmless herbs? A case report of acquired long QT syndrome and torsades de pointes in a patient taking herbal supplements. https://pmc.ncbi.nlm.nih.gov/articles/PMC9123311/
- Berberine Poisoning with Polymorphic Ventricular Tachycardia: A Case Report. https://pmc.ncbi.nlm.nih.gov/articles/PMC13517994/
- Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41543854/
Methodology: Subpages evidence-led supplement pipeline v1